Trial Profile
Efficacy and Safety Evaluation of IBI308 in Patients With Relapsed/Refractory Extranodal NK/T Cell Lymphoma, Nasal Type: a Multicenter, Single Arm, Phase 2 Study (ORIENT-4)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Sintilimab (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- Acronyms ORIENT-4
- Sponsors Innovent Biologics
- 18 Nov 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results (Data cut off Jan 17, 2020) assessing the updated efficacy and safety results with extended follow-up, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2020 Results published in Innovent Biologics data Media Release.